mounjaro tirzepatide prescribing information fda label pdf These highlights do not include all the needed to use safely and effectively. See full information for MOUNJARO. MOUNJARO® (tirzepatide) Injection, for subcutaneous use Initial U.S. Approval: 2022 Mounjaro generic availability (2026) |
Description
Monitoring your weight and measurements, like waist and hip size, provides valuable insights into body composition changes that may not always be visible on the scale
These side effects are usually mild and generally resolve on their own within a few hours or days
Consider high-protein meal delivery to remove the guesswork
The first ANDA filer with a Paragraph IV certification is entitled to 180 days of generic marketing exclusivity
If you experience any of these, check your blood pressure immediately and contact PlexusDx or your doctor
Effects of GLP-1 on appetite and weight
